Abstract
Despite the effectiveness of the selective estrogen receptor (ER) modulators in preventing ER-positive breast cancer, chemopreventive agents still need to be developed for the prevention of ER-negative breast cancers. The naturally occurring retinoids are promising agents for the prevention of human cancers but are too toxic for long-term chronic use. We previously demonstrated that the chemopreventive effects of the retinoids could be separated from the toxicity by using an RXR-selective retinoid, LGD1069. The studies described here demonstrate that LGD1069 effectively suppresses ER-negative tumor development in mouse mammary tumor virus-erbB2 transgenic mice with minimal toxicity. These studies suggest that receptor-selective retinoids are promising agents for the prevention of breast cancer and that they may be particularly useful in preventing ER-negative breast cancer.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Anticarcinogenic Agents / pharmacology*
-
Bexarotene
-
Cell Division / drug effects
-
Female
-
Gene Expression / drug effects
-
Genes, erbB-2
-
Mammary Glands, Animal / cytology
-
Mammary Glands, Animal / drug effects
-
Mammary Neoplasms, Experimental / genetics
-
Mammary Neoplasms, Experimental / metabolism
-
Mammary Neoplasms, Experimental / pathology
-
Mammary Neoplasms, Experimental / prevention & control*
-
Mammary Tumor Virus, Mouse
-
Mice
-
Mice, Transgenic
-
Receptors, Estrogen / physiology
-
Receptors, Retinoic Acid / metabolism*
-
Retinoid X Receptors
-
Tetrahydronaphthalenes / pharmacology*
-
Transcription Factors / metabolism*
-
Transgenes / drug effects
-
Transgenes / genetics
Substances
-
Anticarcinogenic Agents
-
Receptors, Estrogen
-
Receptors, Retinoic Acid
-
Retinoid X Receptors
-
Tetrahydronaphthalenes
-
Transcription Factors
-
Bexarotene